MDB.WAR Medicofarma Biotech S.A.

Healthcare Biotechnology Warsaw Stock Exchange
0.3640 PLN
Close of Oct 29, 2026
0.3360 0.5880
Market cap
PLN 22.8M
P/E
-
P/B
5.55x
ROE
-52.1%
Dividend yield
-
Fundamental score
0.4/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MDB.WAR undervalued?

Graham number

The Graham number of Medicofarma Biotech S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medicofarma Biotech S.A. fundamental analysis

2 of 21 checks passed

ROE 0/2

Low return on equity (-52.1%), below 10%.

ROA 1/1

Return on assets (-17.5%) is above the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (3.0%) is above the industry median (2.6%).

Revenue Growth 0/2

Revenue shrank 69.6% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash runway cannot be calculated.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (5.1x) is above the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Medicofarma Biotech S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medicofarma Biotech S.A.

Medicofarma Biotech SA engages in the research and development of medicines, medicinal products, and biotechnology products in Poland. The company offers staff support and equipment during the early stages of development of generic pharmaceutical products and cosmetics, as well as analytical examinations. It also provides MediPAN COVID SARS-CoV-2 test, a screening test for detecting the SARS-CoV-2 virus; and real-time PCR genetic tests. The company was formerly known as Inbo…

Full company profile